Haohai Biotec 昊海生科
7 significant filings since 30 May 2026: 5 on dividend, 1 on buyback and 1 on legal representative change. The latest, on 14 Sep 2026: 上海市锦天城律师事务所关于上海昊海生物科技股份有限公司差异化权益分派事项的法律意见书.
自 30 May 2026 起有 7 份重大公告：dividend 5 份、buyback 1 份、legal representative change 1 份。最新一份（14 Sep 2026）：上海市锦天城律师事务所关于上海昊海生物科技股份有限公司差异化权益分派事项的法律意见书。
As of 25 Sep 2026 截至2026年9月25日
Haohai Biotec 昊海生科, listed in 2019, operates in the medical devices industry. The company reported lower revenue and profit in 2025 compared to 2024, with attributable net profit down 40.3% at RMB251.0m and revenue down 8.3% at RMB2.47bn. Profit quality remains strong, with operating cash flow to net profit at 2.36x. Financial health is stable, with liabilities to assets at 16.8% as of 30 Jun 2026, a current ratio of 3.49 and a quick ratio of 2.95. However, the share price has declined sharply, falling 40.4% over one year to RMB29.91 on 24 Sep 2026. The six-month results for 2026 show continued declines in profit and revenue. The actual controllers are 蒋伟 and 游捷, with 蒋伟 as the largest holder at 29.07%.
昊海生科2019年上市，属于医疗器械行业。公司2025年营业收入为24.73亿元，同比下降8.3%；归母净利润为2.51亿元，同比下降40.3%。扣非净利润同比下降57.7%。盈利质量良好，2025年经营现金流与净利润之比为2.36倍。截至2026年6月30日，资产负债率为16.8%，流动比率3.49，速动比率2.95，财务状况稳健。但股价大幅下跌，2026年9月24日收盘价为29.91元，一年复权跌幅达40.4%。2026年上半年营收和利润继续下滑。实际控制人为蒋伟、游捷，蒋伟为第一大股东，持股29.07%。
| Flag 标记 | Risk 风险 | Mechanism 影响机制 |
|---|---|---|
| Share price down 40% or more in a year 股价一年下跌40%或以上 | The share price has fallen more than 40% in one year. 股价一年内下跌超过40%。 | A sharp share price decline reduces the company's market valuation. The drop from RMB50.17 to RMB29.91 over one year is shown in the price data. This may affect future capital raising, though no filing specifies a cause. 股价大幅下跌会降低公司市值。一年内从50.17元跌至29.91元为价格数据所示。这可能影响公司未来融资，但无文件说明原因。 |
- Change in attributable net profit for the full year 2026 compared to 2025.
2026全年归母净利润相比2025年的变动情况。 - Revenue trend in the full year 2026 versus 2025.
2026全年营业收入相比2025年的变化趋势。 - Operating cash flow to net profit ratio in 2026.
2026年经营现金流与净利润之比。 - Inventory days as of 31 Dec 2026.
截至2026年12月31日的存货周转天数。 - Any change in the shareholding of the actual controllers 蒋伟 and 游捷.
实际控制人蒋伟、游捷的持股比例是否发生变化。 - Next distribution announcement, including amount and ex-date.
下一次分红公告，包括金额和除权除息日。
- Company: Haohai Biotec 昊海生科, Shanghai Stock Exchange 688366; industry Medical Devices; listed 30 Oct 2019.
公司：昊海生科，上海证券交易所 688366；行业：医疗器械；上市日期：2019年10月30日。 - Close on 24 Sep 2026 RMB29.91; close on 24 Sep 2025 RMB51.98, RMB50.17 in today's terms; one-year change, adjusted for distributions and share changes -40.4%.
2026年9月24日收盘价29.91元；2025年9月24日收盘价51.98元（前复权50.17元）；一年涨跌幅（复权）-40.4%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB28.36 to RMB51.35.
52周区间（前复权）28.36元至51.35元。 - Market capitalisation RMB6.84bn; P/E TTM 44.9; price to book 1.29x.
总市值68.44亿元；市盈率（TTM）44.9；市净率1.29倍。 - Revenue 2025 RMB2.47bn; 2024 RMB2.70bn; change -8.3%.
营业收入2025年24.73亿元；2024年26.98亿元；同比-8.3%。 - Attributable net profit 2025 RMB251.0m; 2024 RMB420.4m; change -40.3%.
归属于母公司股东的净利润2025年2.51亿元；2024年4.20亿元；同比-40.3%。 - Net profit excluding non-recurring items, 2025 change -57.7%.
2025年扣除非经常性损益后的净利润同比-57.7%。 - Basic EPS 2025 RMB1.08; 2024 RMB1.80.
基本每股收益2025年1.08元；2024年1.80元。 - Operating cash flow per share 2025 RMB2.13; 2024 RMB2.78; operating cash flow to net profit 2.36x.
每股经营现金流2025年2.13元；2024年2.78元；经营现金流与净利润之比2.36倍。 - 2025 gross margin 70.1%; net margin 8.4%; ROE 4.5%.
2025年毛利率70.1%；净利率8.4%；净资产收益率4.5%。 - At 30 Jun 2026: liabilities to assets 16.8%; current ratio 3.49; quick ratio 2.95; receivable days 41; inventory days 231.
截至2026年6月30日：资产负债率16.8%；流动比率3.49；速动比率2.95；应收账款周转天数41；存货周转天数231。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB1.18bn, change -9.6%; attributable net profit RMB112.6m, change -46.6%; operating cash flow per share RMB0.56.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入11.79亿元，同比-9.6%；归母净利润1.13亿元，同比-46.6%；每股经营现金流0.56元。 - Ownership: actual controller 蒋伟,游捷; largest holder at 30 Jun 2026: 蒋伟, 29.07%.
股权：实际控制人：蒋伟,游捷；2026年6月30日第一大股东：蒋伟，持股29.07%。 - Latest distribution: ex-date 18 Sep 2026, cash RMB0.25 per share.
最近一次分配：除权除息日2026年9月18日，每股现金0.25元。 - Aurelian Grade D, score 46.5 of 100, graded within a peer group of 140 companies in its industry; no rank among peers is given.
金源评级D，得分46.5（满分100），于行业同业140家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。